NeoTherapeutics Inc.
- Share via
The Irvine biopharmaceutical incurred a third-quarter net loss of $13.2 million, or $1.27 a share, which included a noncash charge of $1 million from the sale of convertible preferred stock of its NeoGene unit. The net loss for the same period last year was $5.3 million, or 70 cents a share. Revenue was not reported.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
